Retour au classement

Bruker Corporation (BRKR)

NEUTRAL
HealthcareMedical DevicesUnited States

Fondamental

40

Prix

$57.28

Capitalisation boursière

$8.94B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilan & Liquidités

Chiffre d'affaires

$3.50B

12 derniers mois (au 30/06/2026)

Résultat net

$-71M

12 derniers mois (au 30/06/2026)

Flux de trésorerie libre

$43M

Capitaux propres totaux

$2.46B

Passif total

$3.73B

Ratio de liquidité général

1.85

Couverture des intérêts

0.50

Dette/EBITDA

6.33

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

Surévalué

Juste valeur

$44.24

Prix actuel

$57.28

Marge de sécurité

-29.5%

Fourchette de juste valeur

$28.76 - $59.73

Méthodes d'estimation

Analyst Target:$58.75
DCF:$24.90
PE-based:-
Graham Growth:-
EPV:-
Consensus des analystes:Acheter (14B / 6H / 1S)
Dernière surprise sur les résultats:+24.87%

Indicateurs de valorisation

Ratio P/E

-

ROE

-0.4%

Ratio P/B

3.62

P/FCF

92.45

Marge brute

46.4%

ROIC

-0.5%

Radar de rentabilité

Value Creation (Economic Moat)

ROIC

-0.5%

WACC

9.8%

ROIC − WACC

-10.3 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Critères d'analyse fondamentale

Réussi (10)

  • Price CAGR 10.89%
  • Gross Margin 46.4%
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Revenue Growth 5Y 11.6%
  • Analyst Consensus 67% Buy
  • Earnings Surprise avg 19.0%
  • Share Dilution -61.5%
  • Piotroski F-Score 5/9

Échoué (13)

  • EPS shows upward trend
  • ROIC -0.5%
  • P/FCF 92.45
  • P/B Ratio 3.62
  • Operating Margin -0.9%
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • DCF valuation (Overvalued)
  • ROE -2.9%
  • Net Margin Trend -2.0% vs 2.3%

Indisponible (4)

  • Dividend Payout NaN%
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Score F de Piotroski

5/9

Signaux mixtes : certains domaines nécessitent attention

score
criteria

Qualité des bénéfices

-

Qualité faible : examiner la comptabilité

Dilution du capital

-61.5%

Rachat d'actions. Favorable aux actionnaires

Gouvernance

Équipe dirigeante

NomTitreÂge
Dr. Frank H. Laukien Ph.D.Chairman, CEO & President65
Dr. Mark R. Munch Ph.D.Corporate Executive VP and President of Bruker Nano Group & Corporate63
Dr. Falko Busse Ph.D.President of Bruker BioSpin Group58
Dr. Burkhard Prause Ph.D.President and CEO of Bruker Energy & Supercon Technologies, Inc.58

Risque d'audit

7

Risque du conseil

6

Risque de rémunération

6

Risque droits des actionnaires

4

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Latest News

Recent headlines for BRKR, sourced from Markets Gazette.

No recent news for BRKR.